DK2658831T3 - elution - Google Patents
elution Download PDFInfo
- Publication number
- DK2658831T3 DK2658831T3 DK11808853.3T DK11808853T DK2658831T3 DK 2658831 T3 DK2658831 T3 DK 2658831T3 DK 11808853 T DK11808853 T DK 11808853T DK 2658831 T3 DK2658831 T3 DK 2658831T3
- Authority
- DK
- Denmark
- Prior art keywords
- reaction
- eluent
- facbc
- radiofluorination
- radiofluorination reaction
- Prior art date
Links
- 238000010828 elution Methods 0.000 title claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 64
- 239000003480 eluent Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- NTEDWGYJNHZKQW-KWCOIAHCSA-N 1-amino-3-fluoranylcyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC([18F])C1 NTEDWGYJNHZKQW-KWCOIAHCSA-N 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 18
- 239000000700 radioactive tracer Substances 0.000 claims description 13
- 229940027541 fluciclovine f-18 Drugs 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 125000002091 cationic group Chemical group 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 claims description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical group [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 2
- NGPJVAAJLVDZCP-NRWMXTQASA-N (8R,9S,13S,14S)-15-(18F)fluoranyl-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound [18F]C1[C@@H]2[C@](C(C1)O)(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 NGPJVAAJLVDZCP-NRWMXTQASA-N 0.000 claims 6
- 238000005349 anion exchange Methods 0.000 claims 4
- 150000004696 coordination complex Chemical class 0.000 claims 3
- 238000002600 positron emission tomography Methods 0.000 claims 3
- UXCAQJAQSWSNPQ-KXMUYVCJSA-N 1-[4-fluoranyl-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C([18F])C1 UXCAQJAQSWSNPQ-KXMUYVCJSA-N 0.000 claims 1
- SMYALUSCZJXWHG-VNRZBHCFSA-N 3-[2-[4-(4-fluoranylbenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1h-quinazolin-4-one Chemical compound C1=CC([18F])=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=S)=O)CC1 SMYALUSCZJXWHG-VNRZBHCFSA-N 0.000 claims 1
- WPKXGJXEAGYSBQ-RVRFMXCPSA-N 4-(2-aminoethyl)-5-fluoranylbenzene-1,2-diol Chemical compound NCCC1=CC(O)=C(O)C=C1[18F] WPKXGJXEAGYSBQ-RVRFMXCPSA-N 0.000 claims 1
- FOTRTWXNJQSQJS-LURJTMIESA-N 4-[(1r)-2-amino-1-hydroxyethyl]-3-fluorobenzene-1,2-diol Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1F FOTRTWXNJQSQJS-LURJTMIESA-N 0.000 claims 1
- XIDVXDKBUJEBSC-NUTRPMROSA-N 5-(18F)fluoranyl-2-nitro-1H-imidazole Chemical compound [18F]C=1N=C(NC=1)[N+](=O)[O-] XIDVXDKBUJEBSC-NUTRPMROSA-N 0.000 claims 1
- QHJLPOSPWKZACG-UHFFFAOYSA-N N-Methylspiperone Chemical compound C1CN(CCCC(=O)C=2C=CC(F)=CC=2)CCC21C(=O)N(C)CN2C1=CC=CC=C1 QHJLPOSPWKZACG-UHFFFAOYSA-N 0.000 claims 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004884 fluconazole Drugs 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 28
- 229910001868 water Inorganic materials 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- ZCXUVYAZINUVJD-GLCXRVCCSA-N [18F]fluorodeoxyglucose Chemical compound OC[C@H]1OC(O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-GLCXRVCCSA-N 0.000 description 15
- 239000002243 precursor Substances 0.000 description 15
- 238000003860 storage Methods 0.000 description 14
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- NTEDWGYJNHZKQW-DGMDOPGDSA-N fluciclovine ((18)F) Chemical compound OC(=O)[C@]1(N)C[C@H]([18F])C1 NTEDWGYJNHZKQW-DGMDOPGDSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000002372 labelling Methods 0.000 description 7
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 5
- 239000002739 cryptand Substances 0.000 description 5
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical group [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 5
- 239000012217 radiopharmaceutical Substances 0.000 description 5
- 229940121896 radiopharmaceutical Drugs 0.000 description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 description 5
- HIIJZYSUEJYLMX-JZRMKITLSA-N 1-fluoranyl-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound [18F]CC(O)CN1C=CN=C1[N+]([O-])=O HIIJZYSUEJYLMX-JZRMKITLSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000003682 fluorination reaction Methods 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- -1 K2CO3 Chemical class 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008364 bulk solution Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- UXCAQJAQSWSNPQ-ZIVQXEJRSA-N 1-[(2r,4s,5r)-4-fluoranyl-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H]([18F])C1 UXCAQJAQSWSNPQ-ZIVQXEJRSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000005323 carbonate salts Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- AOYNUTHNTBLRMT-MXWOLSILSA-N 2-Deoxy-2(F-18)fluoro-2-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H]([18F])C=O AOYNUTHNTBLRMT-MXWOLSILSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241001163743 Perlodes Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QYHYQHPUNPVNDV-UHFFFAOYSA-N aluminane Chemical compound C1CC[AlH]CC1 QYHYQHPUNPVNDV-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000005102 attenuated total reflection Methods 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000005292 fiolax Substances 0.000 description 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- QJEHIIJVWXGJAB-UHFFFAOYSA-M fluoromethyl-(2-hydroxyethyl)-dimethylazanium;chloride Chemical compound [Cl-].FC[N+](C)(C)CCO QJEHIIJVWXGJAB-UHFFFAOYSA-M 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical class OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000007141 radiochemical reaction Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B9/00—General methods of preparing halides
- C01B9/08—Fluorides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061427839P | 2010-12-29 | 2010-12-29 | |
| PCT/EP2011/073670 WO2012089594A1 (en) | 2010-12-29 | 2011-12-21 | Eluent solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2658831T3 true DK2658831T3 (en) | 2017-04-24 |
Family
ID=45495902
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11808853.3T DK2658831T3 (en) | 2010-12-29 | 2011-12-21 | elution |
| DK12806500.0T DK2793954T3 (da) | 2010-12-29 | 2012-12-21 | 18f-fluciclovin-sammensætninger i citratbuffere |
| DK20196030.9T DK3766522T3 (da) | 2010-12-29 | 2012-12-21 | Automatiseret fremgangsmåde til fremstillingen af 18f-fluciclovin-sammensætninger |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12806500.0T DK2793954T3 (da) | 2010-12-29 | 2012-12-21 | 18f-fluciclovin-sammensætninger i citratbuffere |
| DK20196030.9T DK3766522T3 (da) | 2010-12-29 | 2012-12-21 | Automatiseret fremgangsmåde til fremstillingen af 18f-fluciclovin-sammensætninger |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11504430B2 (enExample) |
| EP (2) | EP2658831B1 (enExample) |
| JP (1) | JP6018581B2 (enExample) |
| KR (3) | KR20130132892A (enExample) |
| CN (2) | CN103270004A (enExample) |
| AU (1) | AU2011351550B2 (enExample) |
| BR (2) | BR112013015396B1 (enExample) |
| CA (1) | CA2823063C (enExample) |
| DK (3) | DK2658831T3 (enExample) |
| ES (2) | ES2621950T3 (enExample) |
| MX (1) | MX363538B (enExample) |
| PL (2) | PL2658831T3 (enExample) |
| PT (2) | PT2793954T (enExample) |
| RU (1) | RU2608932C2 (enExample) |
| SG (1) | SG10201805198TA (enExample) |
| WO (1) | WO2012089594A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130132892A (ko) * | 2010-12-29 | 2013-12-05 | 지이 헬쓰케어 리미티드 | 용리제 용액 |
| CA2852840A1 (en) * | 2011-10-19 | 2013-04-25 | Piramal Imaging Sa | Improved method for production of f-18 labeled a.beta. ligands |
| JP6446268B2 (ja) * | 2011-12-21 | 2018-12-26 | ジーイー・ヘルスケア・リミテッド | クエン酸緩衝液中の１８ｆ−フルシクロビン組成物 |
| GB201411569D0 (en) | 2014-06-30 | 2014-08-13 | Ge Healthcare Ltd | Novel formulation and method of synthesis |
| US11534494B2 (en) | 2011-12-21 | 2022-12-27 | Ge Healthcare Limited | Formulation and method of synthesis |
| GB201214220D0 (en) * | 2012-08-09 | 2012-09-19 | Ge Healthcare Ltd | Radiosynthesis |
| GB201221266D0 (en) | 2012-11-27 | 2013-01-09 | Ge Healthcare Ltd | Aldehyde compositions |
| GB201305687D0 (en) * | 2013-03-28 | 2013-05-15 | Ge Healthcare Ltd | Radiolabelling process |
| ES3005832T3 (en) | 2013-11-13 | 2025-03-17 | Ge Healthcare Ltd | Dual run cassette for the synthesis of 18f-labelled compounds |
| WO2015143019A2 (en) * | 2014-03-18 | 2015-09-24 | Mayo Foundation For Medical Education And Research | Gaseous f-18 technologies |
| NL2014828B1 (en) * | 2015-05-20 | 2017-01-31 | Out And Out Chemistry S P R L | Method of performing a plurality of synthesis processes of preparing a radiopharmaceutical in series, a device and cassette for performing this method. |
| JP6827709B2 (ja) * | 2016-04-25 | 2021-02-10 | 日本メジフィジックス株式会社 | ２−［１８ｆ］フルオロ−２−デオキシ−ｄ−グルコースの製造方法 |
| US10695450B2 (en) | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
| JP7148121B2 (ja) * | 2018-08-31 | 2022-10-05 | 国立大学法人北海道大学 | 放射性核種１８ｆの精製方法 |
| GB202005282D0 (en) | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
| US20230390426A1 (en) * | 2020-10-22 | 2023-12-07 | Nihon Medi-Physics Co., Ltd. | Method for producing radioactive zirconium complex |
| JP7127164B2 (ja) * | 2021-01-19 | 2022-08-29 | 日本メジフィジックス株式会社 | ２－［１８ｆ］フルオロ－２－デオキシ－ｄ－グルコースの製造方法 |
| CN113372399A (zh) * | 2021-06-04 | 2021-09-10 | 江苏华益科技有限公司 | 一种氟[18f]脱氧葡糖注射液的合成方法 |
| CN119591463B (zh) * | 2024-11-27 | 2025-12-09 | 遵义医科大学 | 一种 [18f] 三氟甲基末端烯烃的放射性标记方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5425063A (en) * | 1993-04-05 | 1995-06-13 | Associated Universities, Inc. | Method for selective recovery of PET-usable quantities of [18 F] fluoride and [13 N] nitrate/nitrite from a single irradiation of low-enriched [18 O] water |
| ZA978758B (en) * | 1996-10-02 | 1999-03-30 | Du Pont Merck Pharma | Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents |
| RU2165266C1 (ru) * | 2000-06-28 | 2001-04-20 | Центральный научно-исследовательский рентгенорадиологический институт | Способ получения [2-18f]-2-дезоксиглюкозы |
| EP1356827A1 (en) | 2002-04-24 | 2003-10-29 | Mallinckrodt Inc. | Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution |
| BR0215913A (pt) | 2002-11-05 | 2005-08-09 | Ion Beam Applic Sa | Composição de radiofármacos rotulados com 18-f e processo para obtê-los |
| GB0422004D0 (en) * | 2004-10-05 | 2004-11-03 | Amersham Plc | Method of deprotection |
| GB0425501D0 (en) * | 2004-11-19 | 2004-12-22 | Amersham Plc | Fluoridation process |
| US7235216B2 (en) * | 2005-05-01 | 2007-06-26 | Iba Molecular North America, Inc. | Apparatus and method for producing radiopharmaceuticals |
| GB0524851D0 (en) * | 2005-12-06 | 2006-01-11 | Ge Healthcare Ltd | Radiolabelling method using polymers |
| WO2007148088A2 (en) * | 2006-06-21 | 2007-12-27 | Ge Healthcare Limited | Radiopharmaceutical products |
| US20100056826A1 (en) | 2006-11-09 | 2010-03-04 | Nihon Medi-Physicis Co., Ltd. | Radioactive diagnostic imaging agent |
| US8790620B2 (en) | 2006-12-21 | 2014-07-29 | Nihon Medi-Physics Co., Ltd. | Radioactive diagnostic imaging agent |
| EP2119458B9 (en) | 2007-02-13 | 2013-08-21 | Nihon Medi-Physics Co., Ltd. | Method for production of radiation diagnostic imaging agent |
| EP2017359A3 (en) * | 2007-06-11 | 2009-08-05 | Trasis S.A. | Method for the elution of 18F fluoride trapped on an anion-exchange resin in a form suitable for efficient radiolabeling without any evaporation step |
| KR101009712B1 (ko) | 2007-02-22 | 2011-01-19 | 재단법인 아산사회복지재단 | 양성자성 용매와 이에 녹는 염들을 이용한 음이온 교환고분자 지지체로부터의 플루오린-18 플루오라이드 용리와이를 이용한 플루오린-18의 표지방법 |
| US20100150835A1 (en) * | 2007-02-27 | 2010-06-17 | Bengt Langstrom | Synthesis of [18F] Fluoromethyl Benzene Using Benzyl Pentafluorobenzenesulfonate |
| EP1990310A1 (en) * | 2007-04-23 | 2008-11-12 | Trasis S.A. | Method for the preparation of reactive 18F fluoride, and for the labeling of radiotracers, using a modified non-ionic solid support and without any evaporation step |
| WO2009045535A2 (en) * | 2007-10-04 | 2009-04-09 | Sloan-Kettering Institute For Cancer Research | Fluorine-18 derivative of dasatinib and uses thereof |
| US8269035B2 (en) | 2007-12-19 | 2012-09-18 | Nihon Medi-Physics Co., Ltd. | Process for production of radioactive-fluorine-labeled organic compound |
| US20090171272A1 (en) | 2007-12-29 | 2009-07-02 | Tegg Troy T | Deflectable sheath and catheter assembly |
| EP2238074A2 (en) * | 2008-01-03 | 2010-10-13 | GE Healthcare UK Limited | Fluoride processing method |
| EP2110367A1 (en) * | 2008-04-14 | 2009-10-21 | Bayer Schering Pharma Aktiengesellschaft | Purification strategy for direct nucleophilic procedures |
| GB0819293D0 (en) * | 2008-10-21 | 2008-11-26 | Hammersmith Imanet Ltd | Radiofluorination |
| CN102239130A (zh) * | 2008-12-04 | 2011-11-09 | 拜耳先灵医药股份有限公司 | 放射性同位素标记的赖氨酸和鸟氨酸衍生物、它们的用途和制备方法 |
| TW201033713A (en) | 2009-03-03 | 2010-09-16 | Wintek Corp | Reflective color-changing liquid crystal display |
| CA2801530C (en) * | 2010-06-04 | 2017-09-12 | Piramal Imaging Sa | Method for production of f-18 labeled amyloid beta ligands |
| KR20130132892A (ko) * | 2010-12-29 | 2013-12-05 | 지이 헬쓰케어 리미티드 | 용리제 용액 |
| GB201214220D0 (en) * | 2012-08-09 | 2012-09-19 | Ge Healthcare Ltd | Radiosynthesis |
-
2011
- 2011-12-21 KR KR1020137017012A patent/KR20130132892A/ko not_active Ceased
- 2011-12-21 PL PL11808853T patent/PL2658831T3/pl unknown
- 2011-12-21 CN CN2011800634887A patent/CN103270004A/zh active Pending
- 2011-12-21 BR BR112013015396-2A patent/BR112013015396B1/pt active IP Right Grant
- 2011-12-21 KR KR1020197001271A patent/KR102218263B1/ko active Active
- 2011-12-21 JP JP2013546670A patent/JP6018581B2/ja active Active
- 2011-12-21 RU RU2013126979A patent/RU2608932C2/ru active
- 2011-12-21 WO PCT/EP2011/073670 patent/WO2012089594A1/en not_active Ceased
- 2011-12-21 ES ES11808853.3T patent/ES2621950T3/es active Active
- 2011-12-21 US US13/997,808 patent/US11504430B2/en active Active
- 2011-12-21 CA CA2823063A patent/CA2823063C/en active Active
- 2011-12-21 DK DK11808853.3T patent/DK2658831T3/en active
- 2011-12-21 EP EP11808853.3A patent/EP2658831B1/en active Active
- 2011-12-21 MX MX2013007699A patent/MX363538B/es unknown
- 2011-12-21 AU AU2011351550A patent/AU2011351550B2/en active Active
- 2011-12-21 CN CN201810077584.0A patent/CN108218650A/zh active Pending
-
2012
- 2012-12-21 SG SG10201805198TA patent/SG10201805198TA/en unknown
- 2012-12-21 PT PT128065000T patent/PT2793954T/pt unknown
- 2012-12-21 DK DK12806500.0T patent/DK2793954T3/da active
- 2012-12-21 BR BR112014015042-7A patent/BR112014015042B1/pt active IP Right Grant
- 2012-12-21 KR KR1020197030135A patent/KR102137348B1/ko active Active
- 2012-12-21 PL PL20196030T patent/PL3766522T3/pl unknown
- 2012-12-21 DK DK20196030.9T patent/DK3766522T3/da active
- 2012-12-21 EP EP20196030.9A patent/EP3766522B1/en active Active
- 2012-12-21 PT PT201960309T patent/PT3766522T/pt unknown
- 2012-12-21 ES ES20196030T patent/ES2917875T3/es active Active
-
2019
- 2019-02-28 US US16/288,650 patent/US20190192660A1/en not_active Abandoned
-
2022
- 2022-10-10 US US17/962,686 patent/US20230068052A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230068052A1 (en) | Eluent solution | |
| JP7657759B2 (ja) | 新規製剤及び合成方法 | |
| EP2793954B1 (en) | 18f-fluciclovine compositions in citrate buffers | |
| JP7424574B2 (ja) | 放射性フッ素標識化合物の製造方法及び放射性医薬組成物の製造方法 | |
| US11534494B2 (en) | Formulation and method of synthesis | |
| Nandy et al. | Evaluation of the radiochemical impurities arising during the competitive fluorination of nosyl group during the synthesis of 3′-deoxy-3′-fluorothymidine,[18 F] FLT | |
| US20220001034A1 (en) | Novel formulation and method of synthesis | |
| WO2025114063A1 (en) | Stabilized method for 18f-labeling | |
| RU2583371C1 (ru) | Способ получения о-(2'-[18f]фторэтил)-l-тирозина | |
| GB2561122B (en) | Composition comprising [18F]-Fluciclovine | |
| NZ624250B2 (en) | 18f-fluciclovine compositions in citrate buffers |